ETFChannel.com
REGN Description — Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious diseases. Co.'s commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. Co.'s products include: EYLEA (aflibercept) injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema; and Dupixent (dupilumab) injection, which is used for the treatment of adult patients with atopic dermatitis.

Company Name: 
Regeneron Pharmaceuticals, Inc.
Website: 
www.regeneron.com
Sector: 
Biotechnology
Number of ETFs Holding REGN: 
119
Total Market Value Held by ETFs: 
$8,908,084,178.8
Total Market Capitalization: 
$68,128,000,000
% of Market Cap. Held by ETFs: 
13.08%
 ETF   REGN Weight   REGN Amount 
 VTI   0.14%   $1,846,163,904         
 VOO   0.17%   $1,450,541,157         
 QQQ   0.44%   $922,832,661         
 SPY   0.17%   $726,491,223         
 IVV   0.17%   $562,709,887         
 VUG   0.28%   $515,247,206         
 XLV   1.35%   $441,502,771         
 USMV   1.48%   $434,313,516         
 VHT   1.14%   $218,822,075         
 IWD   0.28%   $161,296,920         
List of all 119 ETFs holding REGN »
Quotes delayed 20 minutes

Email EnvelopeFree REGN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (3.12 out of 4)
26th percentile
(ranked lower than approx. 74% of all stocks covered)

Analysts Forecast:
REGN Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding REGN | Regeneron Pharmaceuticals, Inc. | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2021, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.